Showing material events only. Routine administrative filings — bylaw amendments, technical fund updates, procedural FD disclosures — are filtered out so the front page stays signal-dense.
6-K
Operational Other
confidence 75%
filed 2026-07-06
VivoPower announces a strategic refocus on its AI data center business and material changes to previously announced separation initiatives for two non-core subsidiaries: (1) Tembo—discontinuing a previously announced special dividend distribution in favor of completing a business combination with Cactus Acquisition Corp. 1 Limited (with SEC Form F-4 under review and anticipated Nasdaq listing); and (2) Caret Digital—replacing a partial spin-off/special dividend with a complete in specie separation and direct listing on a US national securities exchange. These are significant operational and strategic restructurings affecting the company's portfolio and shareholder distributions, but they are not discrete M&A completions, executive changes, or financial events fitting narrower categories. The announcement is material because it materially alters the company's strategic direction and previously disclosed distribution arrangements.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 98%
filed 2026-07-06
Item 3.01
Polar Power received a deficiency letter from Nasdaq on May 1, 2026, for failing to comply with Listing Rule 5550(b) due to reporting only $144,000 in stockholders' equity. Although the company received a compliance extension until October 28, 2026, the filing explicitly states that failure to evidence compliance by that date or upon filing its 2026 periodic report "may be subject to delisting," with Nasdaq providing written notification of delisting if terms are not satisfied. This is a classic delisting-risk disclosure under Item 3.01.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 75%
filed 2026-07-06
Item 1.01
The filing discloses two unregistered equity issuances: (1) 750,131,126 shares of common stock plus 3,250,000 shares of Series E Preferred Stock issued to Project Nickel LLC in exchange for settling a $1.22M convertible note, and (2) 150,000,000 shares of common stock issued to David M. Garrity for $50,000 cash. Both transactions are unregistered private placements under Section 3(a)(9) and Section 4(a)(2) of the Securities Act. The massive dilution (900M+ common shares issued) represents a material capital event that would significantly affect investor assessment of ownership and equity value.
View raw filing on EDGAR →
8-K
Dividend Distribution
confidence 85%
filed 2026-07-06
Item 8.01
The filing explicitly states "This current report on Form 8-K relates to a distribution made to holders of the Certificates issued by the Select Notes Trust LT 2004-1." This is a distribution to certificate holders of a structured trust, which constitutes a dividend or distribution event. The materiality is high because distributions to security holders are typically material to investors assessing returns and cash flows from their holdings.
View raw filing on EDGAR →
8-K
Earnings release
confidence 92%
filed 2026-07-06
Item 2.02
AbbVie disclosed preliminary Q2 2026 financial results and updated full-year 2026 guidance under Item 2.02, including GAAP and adjusted non-GAAP diluted EPS with a $291 million acquired IPR&D and milestones expense impact. The filing provides revised adjusted diluted EPS guidance ranges for both Q2 2026 ($3.57–$3.61) and full-year 2026 ($13.91–$14.11), with supporting detail in Exhibit 99.1, which is characteristic of an earnings release disclosure.
View raw filing on EDGAR →
8-K
Debt Issuance
confidence 35%
filed 2026-07-06
Item 8.01
The filing discloses repurchase of $16.0 million principal of convertible notes for $31.3 million and agreements to repurchase an additional $14.5 million principal for up to $31.0 million. While this is technically a debt reduction (retirement), the disclosure emphasizes the Company's intent to "replace some or all of the cash used to repurchase the Notes with unsecured or limited-collateral debt financing(s)," suggesting a refinancing or debt restructuring activity. However, the core event is debt retirement rather than issuance, and no new debt has yet been issued. This is a borderline case between financial_other (debt restructuring/refinancing) and debt_issuance (if the replacement financing is the material focus).
View raw filing on EDGAR →
8-K
Dividend Distribution
confidence 92%
filed 2026-07-06
Item 8.01
News Corp discloses daily share repurchase activity under its US$1 billion Repurchase Program authorized as of July 15, 2025. The Item 8.01 filing reports specific buyback transactions (8,907,414 Class A shares and 70,004 Class B shares purchased on 06/07/2026 for approximately US$225.7 million combined), with approximately US$347.96 million expended to date under the program. Share repurchases are a form of capital return to shareholders and fall within the dividend_distribution taxonomy as a return-of-capital mechanism, distinct from operational or financial events.
View raw filing on EDGAR →
8-K
Exec Compensation
confidence 92%
filed 2026-07-06
Item 5.02
The disclosure centers on the reinstatement of the Executive Severance Policy on June 29, 2026, which establishes compensatory arrangements for executive officers during a defined transition period. The policy specifies severance payments (1.5x base salary plus target bonus over 18 months), COBRA premium coverage, pro rata bonuses, and career transition assistance for qualifying terminations. This is a material modification to executive compensation and severance terms, distinct from a specific departure or appointment, and falls squarely within Item 5.02(e) compensation disclosure requirements.
View raw filing on EDGAR →
8-K
Exec departure
confidence 95%
filed 2026-07-06
Item 5.02
Monica Bertagnolli resigned as a member of the Board of Directors effective July 1, 2026, due to her new position with the National Academy of Medicine. The disclosure centers on a director's departure from the company, which is a material governance event affecting the composition of the Board. The explicit statement that the resignation was not due to disagreement confirms this is a straightforward departure rather than a conflict-driven exit.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-07-06
Item 7.01
CaliberCos announced the next phase of its real estate fund tokenization strategy, building on Chainlink's oracle platform and leveraging the Company's LINK token holdings. This is a material operational and strategic initiative that represents a significant shift in how the Company is implementing blockchain infrastructure across its real estate investment platform. While the disclosure is operational in nature (a strategic business initiative rather than a specific financial event, M&A transaction, or governance change), it does not fit neatly into the named operational categories and represents a material strategic pivot from "digital asset exposure to digital asset implementation."
View raw filing on EDGAR →
6-K
Operational Other
confidence 75%
filed 2026-07-06
KT Corporation disclosed a mid-term growth strategy (2026–2031) involving transformation into an "AX Platform Company" with significant capital commitments: KRW 4 trillion in cybersecurity/IT systems, KRW 8 trillion in network infrastructure over 3 years, and KRW 6 trillion in AX infrastructure (AI data centers and submarine cables) over 5 years. This is a material strategic and operational initiative that would affect a reasonable investor's assessment of the company's direction and capital allocation, though it is forward-looking and subject to change. The disclosure is operational in nature (business strategy and infrastructure investment) rather than a discrete event like M&A, earnings, or governance action, making `operational_other` the best fit.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 92%
filed 2026-07-06
Item 7.01
The Company disclosed entry into a Capital on Demand™ Sales Agreement (ATM Program) with a $25 million aggregate offering price and reported that 2.6 million shares had already been sold, generating $11.6 million in net proceeds. This is a classic at-the-market (ATM) equity offering—an unregistered or registered continuous equity issuance that dilutes existing shareholders. The fact that proceeds were mandatorily used to pay down debt (per the secured term loan facility requirement) underscores financial stress and the dilutive nature of the capital raise.
View raw filing on EDGAR →
8-K
Financial Other
confidence 75%
filed 2026-07-06
Item 8.01
Strive announced bitcoin purchases (17.76 BTC at ~$59,850/BTC during June 29–July 2, 2026) and provided detailed updates to its balance sheet, including cash, bitcoin holdings, STRC Stock fair value, and share counts as of July 2, 2026. The disclosure includes preliminary Q2 2026 financial data (bitcoin holdings of 19,864 BTC, $144.5M cash, $42.9M STRC Stock value) and historical quarterly metrics. This is a financial update regarding the company's asset composition and capital deployment strategy, not a traditional earnings release, M&A activity, or other named event type. The material nature reflects the company's core strategy of acquiring bitcoin and the significant changes in its balance sheet composition.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-07-06
Item 5.02
The filing discloses the election of Carl R. Christenson as a Class A director of Moog Inc., effective July 1, 2026, following an increase in board size from nine to ten directors. This is a clear appointment of a director with significant public company and executive leadership experience (former CEO and Chairman of Altra Industrial Motion Corp., current IDEX board member). Director appointments are material governance events affecting the composition and oversight of the company.
View raw filing on EDGAR →
6-K
Operational Other
confidence 85%
filed 2026-07-06
EX-99.1
Klarna announced submission of applications to the Utah Department of Financial Institutions and FDIC to establish Klarna Bank USA, a Utah-chartered industrial bank. This represents a material strategic and operational milestone—the company's transition from operating through partner banks to establishing its own U.S. banking subsidiary with independent governance and FDIC insurance. While not a discrete M&A transaction, debt issuance, or other named event type, this regulatory application and proposed charter expansion is a significant operational and strategic development that would affect a reasonable investor's assessment of the company's growth trajectory and competitive positioning in the U.S. market.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-07-06
Item 3.02
The filing discloses an unregistered sale of 97,200.66 common shares for approximately $1,984,000 under Section 4(a)(2) and Regulation D Rule 506, which is a classic private placement. The Item 3.02 designation and the explicit reference to exempt offering mechanics confirm this is a dilutive equity issuance. The sale occurred on July 1, 2026, as part of a continuous private offering.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-07-06
Item 5.07
MongoDB held its Annual Meeting of Stockholders on June 30, 2026, with shareholders voting on four proposals: election of three Class III directors (Archana Agrawal, Hope Cochran, Dwight Merriman), advisory approval of named executive officer compensation, ratification of PricewaterhouseCoopers LLP as independent auditor, and approval of a charter amendment to eliminate supermajority vote requirements. All proposals passed with detailed vote tallies disclosed.
View raw filing on EDGAR →
8-K
M&A activity
confidence 85%
filed 2026-07-06
Item 1.01
This disclosure concerns an amendment to an Equity Purchase Agreement for the sale of Dagley Insurance (a subsidiary acquired in 2021) by Fathom Holdings to D6 Holdings and Nathan Dagley. The amendment modifies material payment terms ($3.0 million purchase price restructured into installments), cancels 278,000 shares, and redefines ongoing service obligations through May 2028. While technically an amendment rather than the original transaction, it materially affects the terms and enforceability of a disposition and would impact investor assessment of the company's capital structure and contingent obligations.
View raw filing on EDGAR →
8-K
Debt Issuance
confidence 95%
filed 2026-07-06
Item 2.03
Lucid Group drew $800 million under an existing Delayed Draw Term Loan facility on July 6, 2026, creating a direct financial obligation. This is a material debt drawdown under Item 2.03, distinct from a covenant breach or new debt arrangement, and represents a significant capital event for the registrant that would affect investor assessment of liquidity and leverage.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 88%
filed 2026-07-06
Item 5.02
Kathryn M. JohnBull was appointed President and CEO effective July 1, 2026, and Steven V. Oroho, Jr. was appointed Chief Financial Officer and Treasurer effective July 1, 2026. The filing also discloses the retirement of Zachary C. Parker as CEO, with detailed employment agreements and compensation arrangements for the new executives.
View raw filing on EDGAR →
8-K
Debt Issuance
confidence 92%
filed 2026-07-06
Item 1.01
Neutron Holdings entered into a new $200.0 million senior secured revolving credit facility with JPMorgan Chase Bank on July 2, 2026, with a maturity date of July 2031 and defined financial covenants including leverage and coverage ratios.
View raw filing on EDGAR →
8-K
Debt Issuance
confidence 35%
filed 2026-07-06
Item 1.02
Neutron Holdings used IPO proceeds to repay $115.0 million in debt, resulting in termination of the Diameter Credit Agreement and release of all liens and guarantees, including Uber's guarantee.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-07-06
Item 8.01
Neutron Holdings completed an initial public offering on July 2, 2026, issuing 6,679,791 shares of Common Stock at $25.00 per share for approximately $167 million in gross proceeds.
View raw filing on EDGAR →
8-K
M&A activity
confidence 97%
filed 2026-07-06
Item 3.02
Solaris Energy Infrastructure completed the acquisition of Global Energy Services Alliance, Inc. on July 1, 2026, pursuant to a Merger Agreement, funded by approximately $55 million in cash and the issuance of approximately 2.88 million Class A shares. The acquisition is expected to strengthen in-house power generation capabilities and be accretive to earnings and free cash flow per share.
View raw filing on EDGAR →
8-K
Governance Other
confidence 72%
filed 2026-07-06
Item 8.01
The filing discloses termination of a memorandum of understanding (MOU) with the FDIC and Indiana DFI that had been in place since August 2024. While the MOU itself was an informal administrative agreement (suggesting prior regulatory concerns), its termination by regulators is a positive governance/regulatory development indicating resolution of the underlying supervisory matter. This is material to investors as it signals improved regulatory standing, though the specific nature of the original MOU's requirements is not detailed in this disclosure.
View raw filing on EDGAR →
8-K
Dividend Distribution
confidence 98%
filed 2026-07-06
Item 8.01
The filing discloses a declared dividend of $9.04 per share on common shares, payable on July 31, 2026 to shareholders of record as of June 30, 2026. This is a straightforward dividend distribution event. The materiality is high given the substantial per-share amount and the fact that dividend declarations are material to shareholders' investment returns.
View raw filing on EDGAR →
8-K
Debt Issuance
confidence 75%
filed 2026-07-06
Item 8.01
The filing discloses a redemption of $26.5 million of the Company's 10.000% senior secured notes due 2029 at 103.000% of par plus accrued interest. While technically a redemption (retirement) of existing debt rather than issuance of new debt, this represents a material modification of the Company's direct financial obligations and capital structure. The redemption is a significant debt management action affecting the registrant's financial position.
View raw filing on EDGAR →
8-K
Workforce Reduction
confidence 95%
filed 2026-07-06
Item 2.05
The filing discloses a committed workforce reduction plan announced on July 6, 2026, in connection with the Coursera-Udemy merger completed May 11, 2026. The Company estimates $8–11 million in charges, primarily severance and healthcare benefits, to be incurred in Q3–Q4 2026. This is a classic Item 2.05 disclosure of exit costs associated with a restructuring decision that materially affects the registrant's cost structure and operational model.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-07-06
Item 3.02
The filing discloses an unregistered sale of 2,931,697 Class S-2 shares for approximately $42.5 million to accredited investors under Section 4(a)(2) and Regulation D. This is a classic dilutive private placement that increases the share count and raises capital, which is material to investors' assessment of ownership dilution and the company's capital structure.
View raw filing on EDGAR →
8-K
Debt Issuance
confidence 92%
filed 2026-07-06
Item 1.01
iPower completed an Additional Optional Closing on July 6, 2026, issuing $2,000,000 principal amount of Series A senior secured convertible notes to an institutional investor in exchange for $1,880,000 in gross proceeds. The convertible notes carry a 6% original issue discount, $2.39 conversion price, and senior secured status, creating a new direct financial obligation under the existing Securities Purchase Agreement framework.
View raw filing on EDGAR →
8-K
M&A activity
confidence 92%
filed 2026-07-06
Item 7.01
Neolara Corp. announced entry into a non-binding letter of intent for a potential acquisition of a Hong Kong-based AI image restoration company, representing the company's "initial step into the AI technology services sector as part of its broader strategic diversification initiative." Although the LOI is non-binding and subject to numerous conditions, the announcement of a material acquisition target and the company's stated strategic pivot constitute a reportable M&A activity event under Item 1.01 framework, even at the LOI stage.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 85%
filed 2026-07-06
Item 8.01
The filing discloses the appointment of two named executives: Scott David Miller as Product & Analytics Lead (effective July 2, 2026) and Thomas Bennett as Data Science / Modeling Lead (effective July 3, 2026). Both appointments are presented as part of management's strategic expansion of technical capabilities and are material to the company's operational and product development strategy. While the Item 8.01 caption is "Other Events," the substance is clearly executive appointment(s) that strengthen core technical infrastructure.
View raw filing on EDGAR →
8-K
Governance Other
confidence 85%
filed 2026-07-06
Item 1.01
The Board approved an amendment to accelerate the expiration of the Company's stockholder rights plan (poison pill) from February 2, 2027 to July 6, 2026, effective immediately. The Board determined that maintaining the rights plan is no longer necessary to serve the best interests of all stockholders, eliminating the Company's anti-takeover defenses.
View raw filing on EDGAR →
8-K
M&A activity
confidence 85%
filed 2026-07-06
Item 8.01
Edgemode entered into a non-binding term sheet on July 1, 2026 regarding the sale of its interest in land sites in Spain to a third-party purchaser for data center development. Although the term sheet is non-binding and subject to due diligence and definitive documentation, the disclosure of a material disposition of real property assets—structured as a share purchase of entities holding the land—constitutes a material M&A activity event. The company also retained a joint venture option, indicating a significant strategic transaction. The materiality is evident from the detailed disclosure of the transaction structure, exclusivity period, and conditions precedent.
View raw filing on EDGAR →
8-K
Debt Issuance
confidence 92%
filed 2026-07-06
Item 2.03
On June 30, 2026, the Company entered into an Exchange Agreement issuing a Promissory Note (Exchange Note) with a principal amount of $1,299,870 bearing 9.5% interest and maturing July 30, 2027, in exchange for cancellation of Series 2 Convertible Preferred Stock. The Exchange Note constitutes a new direct financial obligation with monthly redemption rights and trigger events including delisting and covenant breaches.
View raw filing on EDGAR →
8-K
Governance Other
confidence 70%
filed 2026-07-06
Item 5.03
The Company amended the Certificate of Designations for Series 2 Convertible Preferred Stock, materially modifying security holder rights and preferred share terms including conversion price, anti-dilution provisions, elimination of liquidation event triggers, and removal of forced redemption rights.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-07-06
Item 5.02
The filing discloses the appointment of Lynn Seely, M.D. as a new Class III director to AbCellera's Board of Directors effective June 30, 2026. The principal disclosed action is a person taking a governance role. Dr. Seely is an independent director with substantial biopharmaceutical executive experience, including CEO roles at Lyell Immunopharma and Myovant Sciences, and prior board service at Blueprint Medicines (acquired for $9.1 billion). This is a material governance event affecting the composition and expertise of the board.
View raw filing on EDGAR →
8-K
M&A activity
confidence 92%
filed 2026-07-06
Item 7.01
Splash Beverage Group entered into an exclusive global licensing agreement with Argent BioPharma Limited to acquire worldwide rights to CannEpil®, a cannabinoid-based epilepsy therapeutic. The transaction includes $5.5 million in newly issued preferred equity consideration, a $1 million strategic investment commitment, and represents a material acquisition of intellectual property and commercial rights that aligns with the company's stated strategic transformation toward a cannabinoid biopharmaceutical platform. This constitutes a material acquisition activity under Item 1.01/2.01 framework.
View raw filing on EDGAR →
6-K
Governance Other
confidence 85%
filed 2026-07-06
EX-99.1
CDT Environmental Technology Investment Holdings Ltd called an Extraordinary General Meeting for July 28, 2026, to seek shareholder approval for five material governance and capital structure resolutions: a company name change to 宸邦科技, a 125-fold increase in authorized share capital (from US$250,000 to US$31,250,000), a share consolidation at a 1-for-5 to 1-for-10 ratio, a redesignation of 182,983 Class A shares to Class B shares with enhanced voting rights for the founder, and omnibus director authorizations. These changes would materially affect the company's share structure, voting rights, and investor holdings.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-07-06
Item 5.02
The filing discloses the appointment of Aleksandr Zhandov as Chief Operating Officer and Deputy Chief Executive Officer effective July 6, 2026. While the disclosure includes employment agreement terms (base salary of $120,000, at-will employment, discretionary bonuses and equity), the principal disclosed action is the appointment of a named executive to a senior officer role reporting to the CEO. This is a material governance event affecting the registrant's leadership structure.
View raw filing on EDGAR →
8-K
M&A activity
confidence 85%
filed 2026-07-06
Item 1.01
The Company entered into an Exclusive License Agreement acquiring worldwide rights to CannEpil®, a pharmaceutical product for treatment of epilepsy and seizure disorders, with a 20-year initial term, defined development milestones, and royalty obligations of 15% of net revenue. The transaction includes issuance of $5.5 million in Series D Preferred Stock as consideration, establishing a significant new business line and financial obligation.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-07-06
Item 3.02
The Company issued 5,500 shares of unregistered Series D Convertible Preferred Stock (stated value $1,000 per share, convertible at $0.25 per share subject to a $0.15 floor) to an accredited investor under Section 4(a)(2) and Rule 506(b) as consideration for the CannEpil® license acquisition, with C/M Capital Partners committing to invest at least $1 million within 60 days and a contingent $1 million sales bonus upon achieving $5 million in cumulative net revenue.
View raw filing on EDGAR →
6-K
Operational Other
confidence 75%
filed 2026-07-06
EX-99.1
Bitzero announced a land reservation agreement for approximately 33 hectares in Finland supporting up to 60MW of capacity, representing a strategic expansion of its Nordic development portfolio for HPC and data center infrastructure. This is a material operational milestone reflecting the company's long-term infrastructure strategy, though it is not a binding acquisition or lease (terms to be finalized) and thus does not qualify as ma_activity. The disclosure also includes a routine investor relations engagement with Think Ink for a two-week marketing campaign.
View raw filing on EDGAR →
8-K
M&A activity
confidence 98%
filed 2026-07-06
Item 1.01
ClearOne entered into a definitive Agreement and Plan of Merger on July 1, 2026, whereby its wholly-owned subsidiary will merge with Cortigent, Inc. (a subsidiary of Vivani Medical), with Cortigent surviving as a wholly-owned subsidiary of ClearOne. The transaction involves the issuance of 12.5 million consideration shares, concurrent $10–15 million financing, board and management reconstitution, and a company rename to 'Cortigent Holdings, Inc.,' with Vivani owning 59.4% to 67.5% of the combined company post-closing and expected to close in Q3 2026.
View raw filing on EDGAR →
8-K
M&A activity
confidence 98%
filed 2026-07-06
Item 7.01
Clarivate announced a definitive agreement to divest its Life Sciences & Healthcare segment to Altaris LLC for $600 million in cash and a seller note. This is a material disposition of a business segment representing a significant portion of the company's operations. The transaction includes customary representations, warranties, and covenants, and is expected to close by year-end 2026, with proceeds earmarked for debt reduction and strategic portfolio rationalization.
View raw filing on EDGAR →
8-K
Exec departure
confidence 95%
filed 2026-07-06
Item 8.01
Mr. John Prince's death results in his departure from the Claritev Board of Directors, where he served since June 2023 and held a position on the Audit Committee. While disclosed under Item 8.01 (Other Information) rather than the typical Item 5.02, the substance is a director departure due to death, which is material to investors assessing board composition and audit oversight.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 95%
filed 2026-07-06
The filing discloses Item 5.07 results of a shareholder vote at the Fund's reconvened Annual Meeting held on June 29, 2026, reporting the election of three Trustees (Frank J. Fahrenkopf, Jr., Colin J. Kilrain, and Salvatore J. Zizza) with specific vote tallies. This is a classic shareholder_vote_results disclosure documenting the outcome of a contested trustee election where each nominee received affirmative votes from a majority of outstanding shares.
View raw filing on EDGAR →
8-K
Governance Other
confidence 85%
filed 2026-07-06
Item 5.03
UbuyHoldings, Inc. implemented a 1-for-10 reverse stock split and changed its corporate name to Longevity Diversified Holdings, Inc., with a corresponding ticker symbol change from UBHY to LGVT. Both actions were shareholder-approved amendments to the Articles of Incorporation and materially affect the company's capital structure and corporate identity.
View raw filing on EDGAR →
6-K
Governance Other
confidence 85%
filed 2026-07-06
EX-99.1
Veraxa Biotech AG has scheduled an extraordinary general meeting for 24 July 2026 to seek shareholder approval for three governance and capital structure matters: (1) increase in conditional capital for shareholder options and amendment of Article 3a; (2) increase in capital band and amendment of Article 3d; and (3) increase in the number of Board members from up to seven and amendment of Article 15. These changes would materially affect the company's capitalization structure and board composition.
View raw filing on EDGAR →
6-K
Operational Other
confidence 85%
filed 2026-07-06
EX-99.2
Veraxa Biotech AG announced the initiation of cell line development with ATUM for its lead BiTAC-TCE program, described as a key milestone in translating the therapeutic candidate into a manufacturable product and advancing toward IND/CTA-enabling activities.
View raw filing on EDGAR →